New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 2, 2013
16:08 EDTBGMDBG Medicine obtains CE Mark and launches automated BGM Galectin-3 test
BG Medicine announced that the first automated version of the BGM Galectin-3 blood test has obtained a CE Mark, an important step in the company's commercial strategy. The BGM Galectin-3 test will be distributed through bioMérieux's VIDAS immunoassay platform which includes about 27,000 installed instruments worldwide. bioMérieux is one of four diagnostic instrument manufacturers partnering with BG Medicine to commercialize automated versions of the BGM Galectin-3 test, and the first to obtain a CE Mark. bioMérieux is preparing a phased launch of the test in Europe and in certain other territories that recognize the CE Mark.
News For BGMD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
07:52 EDTBGMDBG Medicine discloses largest customer files petition for bankruptcy protection
In a regulatory filing, BG Medicine disclosed that Health Diagnostic Laboratory, BG Medicine’s largest customer of its BGM Galectin-3 Test with sales that represented approximately 80% of the company’s revenues for the fiscal year ended December 31, 2014 and approximately 60% of the company’s revenues for the fiscal quarter ended March 31, 2015, filed a voluntary petition for bankruptcy protection under Chapter 11 in the United States Bankruptcy Court for the Eastern District of Virginia, Richmond Division. The company has been in discussions with HDL since its bankruptcy filing and HDL has indicated that it intends to continue operating its business, to purchase tests from the company in the ordinary course and has agreed to accelerated payment terms and a limitation on amounts owed to the company on such new orders. Shipments of galectin-3 test kits to HDL resumed on June 15, 2015 in volumes comparable to those that had been shipped immediately prior to the June 7, 2015 bankruptcy filing. On July 2, 2015, in accordance with the post-bankruptcy accelerated payment terms, the company received timely payment from HDL for kit shipments the Company has made to HDL since June 15, 2015. While the company cannot assure you that HDL’s bankruptcy will not have an adverse effect on HDL’s future orders from the company, the company expects to become less reliant on growth from sales of the manual microtiter plate method for galectin-3 testing as automated testing is introduced in the United States in 2015.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use